Clinical efficacy of budesonide foam in patients with ulcerative colitis taking the maximum dose of oral mesalazine -retrospective observational study
Not Applicable
- Conditions
- ulcerative colitis
- Registration Number
- JPRN-UMIN000036077
- Lead Sponsor
- Ohmori Toshihide gastro-Intestinal Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who changed dosage and administration of formulations including steroids and thiopurines during the treatment period.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Difference in Mayo endoscopic subscore (MES) between pre-treatment and post-treatment evaluation (patients treated with budesonide foam for at least 6 weeks)
- Secondary Outcome Measures
Name Time Method Difference in Mayo score between pre-treatment and post-treatment evaluation (patients treated with budesonide foam for at least 6 weeks)